A Multicenter, Postmarketing Observational (Noninterventional) Study to Evaluate the Safety of Fycompa for Injection in Patients With Partial-Onset Seizures (Including Secondarily Generalized Seizures) (Age 4 Years or Older) or Primary Generalized Tonic- Clonic Seizures (Age 12 Years or Older)
Latest Information Update: 04 Jul 2025
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Co Ltd
Most Recent Events
- 27 Jun 2025 Planned End Date changed from 30 Jun 2028 to 15 Jun 2028.
- 27 Jun 2025 Planned primary completion date changed from 30 Jun 2028 to 15 Jun 2028.
- 16 Jan 2025 Status changed from not yet recruiting to recruiting.